SM-164

• CAT Number: I005676
• CAS Number: 957135-43-2
• Molecular Formula: C₆₂H₈₄N₁₄O₆
• Molecular Weight: 1121.42
• Purity: ≥95%
• Target: IAP
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 0.56 nM/0.31 nM/1.1 nM (Ki, XIAP/cIAP-1/cIAP-2)
• InChI: InChI=1S/C62H84N14O6/c1-41(63-3)57(77)65-49-27-13-11-25-47-33-35-53(75(47)61(49)81)59(79)67-55(45-21-7-5-8-22-45)51-39-73(71-69-51)37-17-15-19-43-29-31-44(32-30-43)20-16-18-38-74-40-52(70-72-74)56(46-23-9-6-10-24-46)68-60(80)54-36-34-48-26-12-14-28-50(62(
• InChIKey: LGYDZXNSSLRFJS-YVGVMFSSSA-N
• SMILES: CC(C(=O)NC1CCCCC2CCC(N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CN(N=N4)CCCCC5=CC=C(C=C5)CCCCN6C=C(N=N6)C(C7=CC=CC=C7)NC(=O)C8CCC9N8C(=O)C(CCCC9)NC(=O)C(C)NC)NC

SM-164 (CAT: I005676) is a small molecule inhibitor that targets and inhibits the activity of cellular inhibitors of apoptosis proteins (cIAPs). cIAPs are involved in the regulation of cell survival and apoptosis, and their dysregulation has been implicated in various cancers. SM-164 binds to the BIR3 domain of cIAPs, preventing their interaction with caspases and promoting caspase-mediated apoptosis. By inhibiting cIAPs, SM-164 can induce tumor cell death and has shown promising antitumor activity in preclinical studies. It has been investigated as a potential therapeutic agent for the treatment of various cancers, including hematological malignancies and solid tumors.

Reference

1:Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. Zhang S, Li G, Zhao Y, Liu G, Wang Y, Ma X, Li D, Wu Y, Lu J.PLoS One. 2012;7(12):e51461. doi: 10.1371/journal.pone.0051461. Epub 2012 Dec 11. PMID: 23240027 Free PMC Article2:Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer. Zhou B, Zhang J, Chen G, You L, Zhang TP, Zhao YP.Cancer Lett. 2013 Feb 1;329(1):118-24. doi: 10.1016/j.canlet.2012.10.039. Epub 2012 Nov 8. PMID: 23142291 3:Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis. Yang D, Zhao Y, Li AY, Wang S, Wang G, Sun Y.Breast Cancer Res Treat. 2012 May;133(1):189-99. doi: 10.1007/s10549-011-1752-3. Epub 2011 Sep 7. PMID: 21901386 4:Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller R, Liao J, Yi H, Liu M, Bellail A, Hao C, Sun SY, Ting AT, Wang S.Mol Cancer Ther. 2011 May;10(5):902-14. doi: 10.1158/1535-7163.MCT-10-0864. Epub 2011 Mar 3. PMID: 21372226 Free PMC Article5:Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases. Yang J, McEachern D, Li W, Davis MA, Li H, Morgan MA, Bai L, Sebolt JT, Sun H, Lawrence TS, Wang S, Sun Y.Mol Cancer Ther. 2011 Apr;10(4):658-69. doi: 10.1158/1535-7163.MCT-10-0643. Epub 2011 Jan 31. PMID: 21282353 Free PMC Article6:SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, Miller RS, Yi H, Shangary S, Sun Y, Meagher JL, Stuckey JA, Wang S.Cancer Res. 2008 Nov 15;68(22):9384-93. doi: 10.1158/0008-5472.CAN-08-2655. PMID: 19010913 Free PMC Article